Amgen Advances Maridebart Cafraglutide Toward Mid-Stage Obesity and Liver Fat Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study.

Amgen Inc. (AMGN) is preparing a new Phase 2b trial called “Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight.” The study aims to see if its drug can lower liver fat and body weight in adults with obesity or overweight, a growing health issue that has clear long-term cost and care implications.

The trial will test maridebart cafraglutide, also known as AMG 133, given as a shot under the skin. The goal is to see whether this treatment, used with diet and exercise, can deliver better liver fat reduction and weight loss than a dummy shot.

This is an interventional study where people are randomly assigned to receive either the active drug or placebo. Neither patients nor their doctors will know who is getting which treatment, and the main goal is to measure how well the drug works as a treatment while watching safety.

The record shows the study was first submitted on February 6, 2026, signaling Amgen’s move to push this asset into mid-stage development. The latest update was filed on February 26, 2026, suggesting planning and setup are active even though recruitment has not yet started.

For investors, this update underlines Amgen’s push into obesity and liver disease, areas where peers working on GLP-1 and related drugs have driven sharp stock gains and sector re-rating. If maridebart cafraglutide shows solid weight loss and liver benefits over time, it could support Amgen’s long-term growth story and sentiment, though near-term stock impact will likely be modest until early data arrive.

The trial is not yet recruiting but is actively updated, and further details are available on the ClinicalTrials portal.

To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.